This video demonstrates the performance of a VATS trisegmentectomy on a patient with a left upper lobe cT1aN0 adenocarcinoma.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung
June 14, 2015
Trials evaluating the use of surgery in stage IIIB NSCLC are lacking. This study goes some way to address that and demonstrates that surgery as part of multi-modality therapy may result in a survival benefit.
June 12, 2015
This meta-analysis of published studies evaluated outcomes of multimodality therapy including resection for superior sulcus NSCLC invading the spine. 134 articles were evaluated, which included 135 patients. 63% had induction therapy, and all underwent en bloc resection. 52% had adjuvant therapy. Survival at 3,5, and 10 years was 57%, 42%, and 27
May 28, 2015
In presentations given at the 2014 STSA Annual Meeting in Tucson, Arizona, two experts address lung cancer screening.
May 22, 2015
In this retrospective review of 336 patients treated surgically for early stage NSCLC, the prognostic value of PET SUV was evaluated. Risks of recurrence and death increased steadily as SUV increased.
May 22, 2015
This interesting article summarizes the potential benefits of exercise in patients with lung cancer, including improved exercise capacity and quality of life, and reduced postoperative complications and length of postoperative stay. This modality is safe, and is likely underutilized in this patient population.
May 20, 2015
A pooled analysis of outcomes from two randomized trials involving SBRT or surgery for operable patients with clinical early stage NSCLC was performed. The number of patients was small (58 total) and the follow-up was a median of 35-40 mos. Overall 3-year survival was better in the SBRT group (95% vs 79%; p=0.037) whereas recurrence free survival di
May 19, 2015
Pts with suspected lung cancer underwent sampling of normal-appearingbronchial epithelial cells in the main bronchi, unrelated to the suspected tumor. Gene expression was analyzed and classified. Classification for cancer was about 75% accurate.
May 17, 2015
The most recent WHO classification for lung adenocarcinoma is based on the predominant histologic subtype in the resected tumor. Several studies have validated the use of this classification system for prognostic purposes, but predicting response to adjuvant chemotherapy has not yet been tested.
May 8, 2015
Targeting specific genetic changes in cancer cells offers patients personalized therapy for their tumors. The number of identified abnormalities is rapidly increasing, and determining whether they represent driver mutations or background noise is increasingly difficult. The IBM Watson supercomputer will be used by 10 US cancer centers to identify a